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Platelets and neurons share many similarities including comparable secretory granule
types with homologous calcium-dependent secretory mechanisms as well as
internalization, sequestration and secretion of many neurotransmitters. Thus, platelets
present a high potential to be used as peripheral biomarkers to reflect neuronal
pathologies. The brain-derived neurotrophic factor (BDNF) acts as a neuronal growth
factor involved in learning and memory through the binding of two receptors, the
tropomyosin receptor kinase B (TrkB) and the 75 kDa pan-neurotrophic receptor
(p75NTR). In addition to its expression in the central nervous system, BDNF is found in
much greater quantities in blood circulation, where it is largely stored within platelets.
Levels 100- to 1,000-fold those of neurons make platelets the most important peripheral
reservoir of BDNF. This led us to hypothesize that platelets would express canonical
BDNF receptors, i.e., TrkB and p75NTR, and that the receptors on platelets would bear
significant resemblance to the ones found in the brain. However, herein we report
discrepancies regarding detection of these receptors using antibody-based assays,
with antibodies displaying important tissue-specificity. The currently available antibodies
raised against TrkB and p75NTR should therefore be used with caution to study platelets
as models for neurological disorders. Rigorous characterization of antibodies and
bioassays appears critical to understand the interplay between platelet and neuronal
biology of BDNF.
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Platelets are circulating anucleate cells originating from
megakaryocytes. In addition to their crucial role in hemostasis,
platelets have been proffered as a peripheral model for the study
of neuronal processes as they share many similarities with
neurons (1–3). These include similar secretory granule types
with homologous calcium-dependent secretory mechanisms (4–7)
as well as internalization, sequestration and secretion of many
neurotransmitters (8–10). Moreover, platelet abnormalities are
reported in multiple neurological pathologies (11), suggesting
common pathophysiological mechanisms. Indeed, platelets
express many proteins found in neurons, including serotonin
transporter SERT (12), amyloid precursor protein (APP), and
amyloid b (2). The brain-derived neurotrophic factor (BDNF) is
one such protein present in the central nervous system that is also
found within platelets (13), with concentrations reaching up to
1,000-fold those of neurons (13–15).
In the brain, BDNF is involved in axonal growth through the
binding of the tropomyosin receptor kinase B (TrkB). This
receptor has a highly glycosylated extracellular domain (ECD)
and an intracellular domain (ICD) consisting of a SRC homology
2 domain-containing-transforming protein C (Shc)-binding
domain and a tyrosine kinase region (16, 17). Two truncated
isoforms are also found in the central nervous system: the 95 kDa
TrkB-T1 isoform, lacking both the Shc-binding and tyrosine
kinase domains (18, 19) and the 100 kDa TrkB-T-Shc isoform
that also lacks the tyrosine kinase domain but expresses the Shc-
binding domain (19, 20). Additionally, BDNF is involved in the
myelination of peripheral axons through the binding of the 75
kDa pan-neurotrophic receptor (p75NTR). This receptor is
composed of an ECD consisting of four cysteine-rich domains
(CRD) containing sites for both N- and O-linked glycosylation
(21, 22). The intracellular domain consists of a palmitoylated
chopper domain followed by a death domain (23, 24). The full-
length isoform of the p75NTR receptor has a monomeric
molecular weight varying between 72 and 85 kDa (21, 25–30).
A 62–65 kDa splice variant lacking CRD 2 through 4 has also
been reported (27, 31).
Platelets internalize BDNF and secrete it upon activation (32,
33). While the contribution of the brain-borne BDNF to the
platelet pool is still unclear, circulating levels of BDNF are
associated with multiple neurological diseases, suggesting that
peripheral BDNF could be used as a model of neuronal BDNF
levels (34, 35). TrkB-T1 is found in megakaryocytes (36) and was
recently reported in a platelet proteomic dataset (37); the
presence of the p75NTR mRNA has been reported in platelet
transcriptomic studies (38–41). Nevertheless, BDNF receptors
have not been reported using antibody-based approaches at the
protein level (32, 42). To assess these divergences, we tested multiple
antibodies against TrkB and p75NTR receptors on platelets by
immunoblotting and flow cytometry. Herein, we report important
tissue-specificity among the multiple antibodies raised against TrkB
and p75NTR receptors, highlighting the importance of thorough
antibody characterisation when investigating these receptors.Frontiers in Immunology | www.frontiersin.org 2METHODS
Antibodies and Reagents
Acid citrate dextrose solution A (ACD-A) was purchased from
the Montreal Heart Institute pharmacy (DIN: 00788139).
Prostaglandin E1 (PGE1, catalog no. 1620) was obtained from
Tocris Bioscience. Antibodies against TrkB and p75NTR are
presented in Table 1. Allophycocyanin (APC)-Vio770 isotype
control (catalog no. 130-104-618) was from Miltenyi Biotec.
Mouse IgG1 (catalog no. MAB002) and IgG2B (catalog no.
MAB004) isotypes were from R&D Systems. Alexa Fluor 488-
conjugated donkey anti-mouse IgG and donkey anti-rabbit IgG
were from Thermo Fisher Scientific (catalog no. A21202 and
A21206). The healthy human brain cerebral cortex full tissue
lysate was obtained from Novus Biologicals (cat. NB820-59182).
Proteins were extracted from the cortex of a healthy 66 years old
male using the total protein extraction kit (cat. NBP2-37853).
Proteins were aliquoted and conserved at −80°C until western blot
analyses. U87-MG and U251-MG cells were a gift from Dr. Gaëlle
V. Roullin. Eagle’s minimum essential medium (EMEM) and fetal
bovine serum (FBS) were obtained from Wisent and Thermo
Fisher Scientific. Deglycosylation kits were obtained from New
England Biolabs (catalog no. P0704S and P6044). Platelet integrin
Iba (CD42b) and integrin aIIb (CD41) antibodies were from
Santa Cruz Biotechnology (catalog no. sc-59051 and sc-365938).
Platelet integrin b3 (CD61) antibody coupled to phycoerythrin
(PE) and corresponding control isotype were fromMiltenyi Biotec
(catalog no. 130-110-749 and 130-104-613). Sortilin antibody was
from Abcam (catalog no. ab16640) and lysosomal-associated
membrane protein 1 (LAMP-1) was from the Developmental
Studies Hybridoma Bank (catalog no. H4A3).
Participant Selection
The study protocol was approved by the Montreal Heart Institute
Scientific and Research Ethics Committee (#2018-2368) and
written informed consent was obtained from each participant.
Participants (four females and three males) were healthy adults
aged between 22 and 43 years old, refrained from taking drugs
known to affect platelet function in the 14 days before sampling,
had not undergone major surgery in the last 6 months, did not
have a history of bleeding symptoms and had platelet counts and
hemoglobin levels within normal ranges.
Blood Collection and Platelet Isolation
Whole blood was collected in syringes containing ACD-A
anticoagulant (1:5 ratio) with 21G needles. Blood was
centrifuged at 200g for 15 min and platelet-rich plasma (PRP)
was collected. PGE1 (1 µM) was added to PRP to prevent platelet
activation during isolation. PRP was centrifuged for 10 min at
1,000g to pellet platelets. The supernatant was discarded, and
platelets were resuspended gently in Tyrode’s buffer (137 mM
NaCl, 11.9 mMNaHCO3, 0.4 mMNaH2PO4•2H2O, 2.7 mM KCl,
5.6 mM glucose, 1.1 mMMgCl2, pH 7.4). The purity of the platelet
preparation was verified by flow cytometry. The mean percentage
of events contained within the platelet gate and verified by plateletFebruary 2021 | Volume 12 | Article 606861
Fleury et al. BDNF Receptors in Plateletsintegrin b3 (CD61) labeling was 99.53 ± 0.27%. A representative
flow cytometry readout is shown as Figure S1.
Cell Culture
U87-MG and U251-MG human glioblastoma cells were grown
in EMEM supplemented with 10% FBS and 1% penicillin/
streptomycin mix at 37°C and a fixed CO2 level of 5%. Cells
were washed with phosphate-buffered saline (PBS) prior to
trypsinization. Cells were then pooled down by 800g centrifugation
and washed again in PBS prior to lysis for immunoblotting or
fixation for flow cytometry experiments.
Deglycosylation
Platelets or U87-MG cells were lysed in RIPA buffer (150 mM
NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1% NP40,
0.5% sodium deoxycholate, 0.1% SDS). Proteins from whole cell
lysates were denatured in denaturing buffer (0.5% SDS, 40mM
DTT, B1704S, New England Biolabs, MA, USA) and heated to
100°C for 10 min. Lysates were put on ice and glycobuffer 2, 1%
NP40 and protein N-glycanase F (PNGase F) (P0704S, New
England Biolabs, MA, USA) were added to denatured proteins
for N-deglycosylation. Protein deglycosylation mix II (P6044,
New England Biolabs, MA, USA) containing PNGase F, O-
glycosidase, neuraminidase A, b1-4 galactosidase, and b-N-
acetylhexosaminidase f was used for N and O-deglycosylation
assays. Samples were incubated overnight at 37°C and then
conserved at −80°C until analysis. Glycosylation profiles were
assessed by mass shift on western blots, using the ANT-019
antibody for the TrkB receptor and the HPA004765 antibody for
the p75NTR receptor. Enzymatic activity was verified by
reblotting membranes for N-glycosylated proteins sortilin and
CD42b (N-glycosylation) or CD41 and LAMP-1 (O and
N-glycosylation).Frontiers in Immunology | www.frontiersin.org 3Gel Electrophoresis and Immunoblotting
Platelets were centrifuged in the presence of PGE1 at 1,000g for
10 min, at room temperature (RT). The supernatant was discarded
and platelets were lysed in ice-cold RIPA buffer containing
protease and phosphatase inhibitors. 4X Laemmli’s buffer (250
mM Tris pH 6.8, 8% SDS, 40% glycerol, 20% b-mercaptoethanol,
0.02% bromophenol blue) was added 1:4 to samples and heated at
95°C for 5 min. Proteins were resolved on 8% polyacrylamide gels
and transferred onto 0.45 µm PVDF membranes. Membranes
were blocked in 3% BSA or 5% non-fat dry milk depending of the
primary antibody diluent and incubated at 4°C overnight with the
primary antibody. Membranes were then washed thrice for 10min
in Tris-buffered saline containing 0.1% Tween (TBS-T) and
incubated in secondary antibody conjugated to horseradish
peroxidase (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) at a dilution of 1:10,000 in 5% milk for 60 min.
Membranes were washed thrice in TBS-T and exposed to HRP
substrate (Immobilon Classico Western HRP substrate, Luminata
Classico, EMD Mill ipore, Etobicoke, ON, Canada).
Chemiluminescence was captured on half-blue films (Mandel
Scientific, Guelph, ON, Canada).
Flow Cytometry
Platelets or U87-MG cells were fixed in 1% paraformaldehyde
(PFA) at RT for 15 min. Following fixation, cells for intracellular
labeling were permeabilized by adding 0.1% Triton X-100 for
10 min. Permeabilization was stopped by adding 500 µl of PBS.
Cells were than pooled down and resuspended in PBS. Samples
were labeled with primary antibody or with the corresponding
isotypes for 30 min in the dark at RT. For unconjugated
antibodies, secondary antibodies conjugated to Alexa Fluor 488
were added at a dilution 1:200 and incubated in the dark for
30 min. Cells were gated based on size and granularity. A total ofTABLE 1 | List of antibodies tested.
Target Manufacturer Catalog number Clone Immunoblotting concentration Flow cytometry concentration
TrkB Abcam ab134155 EPR1294 0.5 µg/ml in 5% skim milk –
Abnova Corporation H00004915-M02 3D12 1 µg/ml in 3% BSA –
Alomone Labs ANT-019 Polyclonal 1 µg/ml in 5% skim milk –
Biosensis R-1834 Polyclonal 1 µg/ml in 3% BSA –
Millipore Sigma HPA007637 Polyclonal (1 µg/ml in 5% skim milk) –
Novus Biologicals NBP2-52524 10B6C4 0.5 µg/ml in 3% BSA –
R&D Systems AF1494 Polyclonal 1 µg/ml in 3% BSA –
R&D Systems FAB397G * (FITC) 75133 – 80 to 330 µg/ml
R&D Systems FAB3971G (FITC) 72509 – 40 µg/ml
R&D Systems MAB397 75133 0.5 µg/ml in 3% BSA (20 µg/ml)
R&D Systems MAB3971 72509 (0.5 µg/ml in 3% BSA) 20 µg/ml
Sino Biologicals 10047-MM12 7H6E7B3 (1 µg/ml in 5% skim milk) 40 µg/ml
p75NTR Alomone Labs ANT-007 Polyclonal 0.8 µg/ml in 3% BSA 20 µg/ml
Alomone Labs ANT-011 Polyclonal 0.4 µg/ml in 3% BSA –
Biosensis M-011-100 ME20.4 – [20 to 100 µg/ml]
EMD Millipore 05-446 ME20.4 – 80 to 200 µg/ml
Millipore Sigma HPA004765 Polyclonal 0.3 µg/ml in 5% skim milk –
Miltenyi Biotec REA844 (APC-Vio770) REA844 – 1:25
Miltenyi Biotec 130-113-983 (PE) ME20.4-1.H4 – 1:5
Santa Cruz Biotechnology sc-271708 B1 0.8 µg/ml in 5% skim milk –February 20All other antibodies were indirectly labeled with either donkey anti-mouse or donkey anti-rabbit secondary antibodies conjugated to Alexa Fluor 488. Antibody concentrations for
immunoblotting and flow cytometry are listed either in µg/ml, or in dilution factor of the stock concentration. *custom-made antibody, PE, phycoerythrin; APC, allophycocyanin;— antibody
not used for this application; ( ), Antibody not validated for this application by the manufacturer, [ ], antibody supported but not validated for this application by the manufacturer.
For pre-conjugated antibodies, the associated fluorochrome appears in parenthesis next to the catalog number.21 | Volume 12 | Article 606861
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flow cytometer; data was analyzed using the MACSQuantify
software (version 8.2.1).
Data Analysis
Immunoblotting data is representative of a minimum of three
independent experiments and five healthy volunteers for platelets.
For flow cytometry, data are presented as median (25th percentile;
75th percentile), corrected by isotype control and are representative
of three or more independent experiments. Sample size varies
between three for negative results (i.e., absent or very weak
expression) and 10 for results suggestive of expression for
increased precision.RESULTS
Antibodies Targeting TrkB
TrkB in the Brain and Platelets
Except for mab3971, all antibodies tested identified the 95 kDa
TrkB-T1 isoform in human cortex, while only half displayed the
full-length isoform. Out of the 10 antibodies tested, seven showed a
band directly under the 100 kDa weight marker in platelet samples
(Figure 1A and Figure S2). This finding is in line with the
observation of TrkB-T1 in primary human megakaryocytes by
Labouyrie et al. (36). Furthermore, a band corresponding to the
full-lengthTrkB receptor expected at amolecularweight of 145 kDa
was displayed in platelets only by the NBP2-52524 antibody and
was not present in platelets from all volunteers. As the full-length
TrkB receptor has not yet been reported in platelets or
megakaryocytes, further investigations to confirm the presence of
this isoform in platelets is warranted. Interestingly, mab3971
displayed a band at the molecular weight of 95 kDa in platelet
lysates but failed to detect the TrkB receptor in the human cortex.
On the other hand, three antibodies identified at least the truncated
isoform of the TrkB receptor in the cortex but failed to in platelet
lysates. In addition, all six antibodies that identified the TrkB-T1
isoform inboth cortex andplatelets systematically displayed a lower
band in the cortex, suggesting slight differences betweenTrkB-T1 in
these samples. Interestingly, TrkB-T1originating frombrain tissues
hasalsobeenobserved to runat a slightly lowermolecularmass than
that of other cell types in mice, potentially due to differential
glycosylation (18).
Deglycosylation of the TrkB Receptor
We then tested whether differences in TrkB mass could be
explained by N-glycosylation. In both cell types, the protein
identified by the TrkB antibodies was unaffected by PNGase F
treatment (Figure 1B). Deglycosylation of glycoproteins sortilin
in U87-MG and CD42b in platelets confirmed that PNGase F
was active in the experimental settings. The absence of a mass
shift following PNGase F treatment is in opposition to previous
results reporting that TrkB is N-glycosylated (43), and argues
against glycosylation as the primary cause of different molecular
masses reported here and elsewhere (18).Frontiers in Immunology | www.frontiersin.org 4Cellular Localization of the TrkB Receptor
Flow cytometry was used to assess the localization of the TrkB
protein in human platelets. U87-MG cells were used as a positive
control. A total offive antibodies were tested (Figure 1C, Table 2),
including the mab397 and mab3971 in both direct (preconjugated
to fluorochrome) and indirect labeling (conjugated with
AlexaFluor488 secondary antibody).
All antibodies tested indicate either an absence or very weak
TrkB expression at the membrane of U87-MG cells (Table 2).
For permeabilized cell labeling, the 10047-MM12 antibody
detected TrkB in approximately half of the cells, a result that
was reproduced with mab397 through indirect labeling.
However, the same clone failed to recognize TrkB when
preconjugated to the fluorochrome. Similarly, mab3971
antibody showed a weak proportion of U87-MG cells
expressing TrkB through indirect labeling and resulted in
complete absence of this protein when preconjugated to FITC,
thus failing to bind to the positive control.
In platelets, 10047-MM12 showed TrkB to be expressed at the
surface of approx. half of the platelet population and this
proportion increased to nearly 75% when platelets were
permeabilized (Table 2). A similar pattern was seen with the
indirectly conjugated mab397, albeit to a lesser extent;
preconjugation with the fluorochrome abolished labeling, as for
U87-MG cells. The other antibodies tested showed absence or very
low expression of TrkB at the platelet membrane, and minimal
increases in permeabilized platelets (Table 2).
In summary, only the unconjugated mab397 and 10047-
MM12 showed convincing TrkB signals in U87-MG cells and
both antibodies showed membrane and intracellular labeling of
TrkB in platelets, with a stronger signal in the intracellular
compartment, suggesting that TrkB is present both at the cell
membrane and in the intracellular compartment.
Antibodies Targeting p75NTR
p75NTR in the Brain and Platelets
We then sought to investigate whether platelets expressed the low
affinity BDNF receptor p75NTR by western blotting (Figure 2A and
Figure S3). Themasses for themonomer of p75NTR reported in the
literature vary between 72 and 85 kDa, with 75 kDa being the most
reported (21, 25–30).HPA004765 raisedagainst the ICDandANT-
007raisedagainst theECDbothdisplayedbands at the expected size
of 75 kDa corresponding to the monomeric form of the full-length
receptor in platelet samples. ANT-007 also resulted in bands at
around 80 kDa, and the ANT-011 antibody, which targets the ICD
of p75NTR, resulted in a band at 70-72 kDa in platelets. sc-271708,
also directed against the ICD, did not find any band in this range in
platelets nor cortex lysates. Instead, it identified a protein running
just above the 100 kDamarker that was only seen in platelet lysates.
Interestingly, bands having the samemobility were also found with
the HPA004765 and ANT-007 antibodies when used on platelets,
but not on human cortex lysates. Furthermore, the intensity of this
band in platelets is highly variable from an individual to another
despite equal quantities of platelet lysates loaded into each well, as
further supported by the b-actin used as a loading control. As with
the TrkB receptor, the band found in the cortex lysates for p75NTRFebruary 2021 | Volume 12 | Article 606861
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FIGURE 1 | TrkB expression in human brain and platelets. (A) Healthy human cortex (C; 3 µg) and platelets lysates (platelets; 30 to 75 µg) were analyzed in
denaturing and reducing conditions and blotted with antibodies raised against TrkB extracellular domain. Left: molecular weight marker in kDa. Right: antibody
catalog number. b-actin was used as a loading control. (B) Human glioblastoma cells U87-MG and healthy platelets lysates were either left untreated (Untreated) or
submitted to 37°C overnight in absence (Sham) or presence of N-deglycosylation enzyme PNGase F (PNGase F). Membranes were blotted with ANT-019 antibody
against TrkB ECD. PNGase F activity was confirmed by reblotting membranes with antibodies against N-glycosylated proteins sortilin for U87-MG and CD42b for
platelets. (C) Human glioblastoma U87-MG cells and healthy human platelets isolated from whole blood were fixed or fixed and permeabilized. Cells were labeled with
antibodies directed toward the extracellular domain of the TrkB receptor and analyzed by flow cytometry. Results shown are representative of (A) ≥ 3 independent
experiments and ≥ 5 different platelet samples from different donors and (B, C) 3 independent experiments and 3 different donors for platelets samples.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 12 | Article 6068615
Fleury et al. BDNF Receptors in Plateletsruns slightly below that found in the platelet lysate samples, except
for ANT-011which identifies a single 72 kDa band both in both the
human cortex and platelet lysates.
Deglycosylation of the p75NTR Receptor
We investigated whether the differences in apparent molecular
weights in the brain and platelet lysates originated from a
differential glycosylation pattern. The p75NTR receptor has a
single N-glycosylation site on the first CRD of its ECD and
multiple O-glycosylation sites on its stalk domain. We therefore
used a deglycosylation mix that removes N-glycans as well as the
majority of O-glycans. As shown in Figure 2B, the 75 kDa band
identified in platelets did not shift following deglycosylation,
while deglycosylation decreased the apparent molecular weight
of this band in U251-MG cells. However, the higher band
observed at approx. 100 kDa in platelets either disappeared or
lost intensity in all 3 replicates. The fact that no new band
appeared concomitantly to the loss of the 100 kDa band suggests
that the mass shift engendered by deglycosylation caused the 100
kDa band to merge to the already present 75 kDa band,
suggesting that this higher band could be a highly glycosylated
form of the 75 kDa band observed in platelets.
Cellular Localization of the p75NTR Receptor
We then used flow cytometry to assess p75NTR localization in
human platelets and U87-MG human glioblastoma cells used as a
positive control. A total offive antibodies raised against the p75NTR
receptor ECD were tested, including ANT-007 also tested by
western blotting, and the well-characterized clone ME20.4
(Table 2). The percentage of p75NTR-positive cells varied greatly
depending on the antibody used, not only in platelet samples, but
also in U87-MG cells (Figure 2C and Table 2). Only theFrontiers in Immunology | www.frontiersin.org 6humanized REA844 antibody and the clone ME20.4-1.H4 gave a
positive expression signal in U87-MG cells. All the other
antibodies tested showed close to no signal for both surface and
whole cell labeling in U87-MG cells, including other ME20.4
clones. On platelets, antibodies REA844 and the clone ME20.4-
1.H4 resulted in a signal at the cell surface. While the REA844
offered an increased signal in permeabilized platelets, clone
ME20.4-1.H4 resulted in a weaker signal in permeabilized cells.
In summary, only the REA844 antibody showed convincing
signals in both U87-MG cells and platelets, with large disparities
between antibodies in their ability to bind the receptor in U87-MG
cells contributing to the uncertainty of the results seen in platelets.DISCUSSION
We set out to identify TrkB and p75NTR on human platelets using
antibody-based techniques and tested various commercial
antibodies from different host species and targeting different
epitopes. While both receptors could be detected on human
platelets, we found major discrepancies among antibodies in
their ability to detect BDNF receptors on platelets, but also on
human cortex and U87-MG cells. These results highlight
important challenges in using antibody-based assays to
determine the expression pattern of these receptors, with a
notable lack of reproducibility among the tested antibodies.
TrkB on Platelets
Our immunoblotting experiments suggest the presence of a
truncated form of the TrkB receptor in human platelets
(Table 3). However, major discrepancies were found among
antibodies, as well as between brain and platelet lysates.TABLE 2 | TrkB and p75NTR expression assessed by flow cytometry.
Target Catalog no./clone Fluorochrome Host U87-MG cells Platelets
Surface (%) Whole cell (%) Surface (%) Whole cell (%)

















































































(0.1; 82.7)February 2021 | Volume 12U87-MG cells and platelets were fixed in 1% paraformaldehyde for surface labeling and further permeabilized in 0.1% Triton X-100 for whole cell labeling. Cells were then labeled with
antibodies raised against the extracellular domain of the TrkB or p75NTR receptor. Data represent percentage of positive cells, corrected for isotype control, and are presented as median
(25th; 75th percentile). Data are representative of at least 3 independent experiments. FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin.| Article 606861
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identified TrkB in the cortex at a slightly lower mass to that
seen in platelets. A similar band shift was also reported for TrkB-
T1 in mice, with brain lysates running slightly below NIH/3T3
cells (18). The authors suggested the mass shift was likely due to
differential glycosylation but did not confirm their hypothesis. A
similar hypothesis was also raised by another group facing
challenges to identify TrkB in glial cells (44). Glycosylation on
TrkB appears to be important for antibody recognition, as Eager
et al. showed that the glycans on the ECD of TrkB were necessary
for antibody binding, either by being included in the epitope or
by allowing the correct epitope conformation for antibodyFrontiers in Immunology | www.frontiersin.org 7binding (45). However, PNGase F treatment did not alter the
apparent molecular weight of the bands detected by TrkB
antibodies in platelets nor in the U87-MG cell line in our
study. Because the intensity of the observed 95 kDa band did
not decrease following PNGase F treatment, it seems unlikely
that this is the result of a lack of affinity of the tested antibodies
for the deglycosylated TrkB receptor. A limitation regarding
these experiments is that while PNGase F has a large spectrum, it
does not cleave all N-linked glycans. In addition, we focused on the
glycosylation profile but cannot exclude that the observed mass




FIGURE 2 | p75NTR expression in human brain and platelets. (A) Healthy human cortex (C; 10 µg) and platelets lysates (platelets; 30 µg) were analyzed in denaturing and
reducing conditions and blotted with antibodies raised against p75NTR. Left: molecular weight marker in kDa. Right: antibody catalog number. b-actin was used as a loading
control. (B) U251-MG cells and healthy human platelet lysates were either left untreated (untreated) or submitted to 37°C overnight in absence (Sham) or presence of the
protein deglycosylation mix II (Deglyco). Membranes were blotted with the HPA004765 antibody against p75NTR ICD. Membranes were then stripped and reblotted for
lysosomal-associated membrane protein 1 (LAMP-1) and CD41 as internal controls of enzymatic activity. (C) Human glioblastoma U87-MG cells and healthy human platelets
isolated from whole blood were fixed or fixed and permeabilized. Cells were labeled with antibodies directed toward the p75NTR receptor and analyzed by flow cytometry.
Results displayed are representative of (A) ≥ 3 independent experiments and ≥ 5 different platelet samples from different donors and (B, C) 3 independent experiments and 3
different donors for platelets samples.February 2021 | Volume 12 | Article 606861
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could result in an alternative folding of the protein and alter the
layout of certain epitopes (44, 45). This could explain the many
differences between antibodies observed in flow cytometry, as this
technique labels proteins in their native conformation, rather than
under reducing conditions that can be used in immunoblotting.
Nonetheless, it cannot explain the differences observed between
the same clones through direct and indirect labeling. As we
adjusted for non-specific binding by subtracting the isotype
control fluorescence in our experiments, the difference is
unlikely to arise from non-specific binding. Whether steric
hindrance of fluorochrome-conjugated antibodies could explain
the lack of binding would merit further attention with alternative
fluorochrome conjugates. Taken together, these results highlight
the importance of confirming findings with independent
antibodies and characterizing them against known controls.
p75NTR on Platelets
Our immunoblotting experiments suggest the presence of the
p75NTR receptor in human platelets (Table 4). The 72, 75, and 80
kDa bands identified in platelets by the HPA004765, ANT-007
and ANT-011 antibodies all correspond to molecular weights
reported for the full-length p75NTR receptor (21, 25, 26, 28–30).
Previous studies found that the apparent mass of the receptor
varied depending on reducing conditions (25, 30). While the
masses reported herein are in the same range, all samples were
subjected to identical reducing conditions. Thus, the differences
in weights cannot be attributed to variable reducing conditions.
Furthermore, HPA004765 and ANT-007 antibodies identified
the isoform in the cortex to run slightly below the isoform foundFrontiers in Immunology | www.frontiersin.org 8in platelets. Despite the many glycosylation sites, O and N-
deglycosylation did not lower the apparent molecular weight of
the protein in platelets, in contrast with U251-MG cells as
previously reported (25, 29). Whether other post-translational
modifications, such as palmitoylation, may be the cause of the
mass differences observed (46), and could explain the important
discrepancies observed among the tested antibodies in flow
cytometry, have not been the center of investigation so far.
While bands between 72 and 85 kDa have all been associated to
the monomeric p75NTR receptor (21, 25–30), the band at 100 kDa
is rather associated to a single p75NTR receptor bound by dimeric
nerve growth factor (NGF) (47, 48). However, the study of such a
complex requires cross-linking, which we have not carried out,
and the denaturing and reducing conditions used in our
experiments render the possibility of a non-covalent complex
unlikely. The intensity of the 100 kDa band was decreased or
completely abolished by deglycosylation, suggesting either a highly
post-translationally modified form of the receptor or a strong
complex stabilized by glycans. The fact that this band is displayed
by three antibodies targeting different epitopes suggest that this
band is specific, and the nature of the protein or protein complex it
identifies in platelets warrants further investigation.
Platelets as Neuronal Biomarkers
for BDNF Receptors
Several studies have highlighted alterations in brain TrkB and
p75NTR receptors in neurological disorders. For instance, the
TrkB receptor levels have been shown to be decreased in the
brain of schizophrenic patients (49), while alterations in p75NTR
cleavage is believed to lead to neuronal death in Alzheimer’sTABLE 3 | Summary of antibody performance for TrkB.
TrkB
Manufacturer Catalog no. Host Detection in cortex Detection in platelets
TrkB-FL TrkB-T1 TrkB-FL TrkB-T1
Abnova Corporation H00004915-M02 Mouse + + – +
Sino Biologicals 10047-MM12 + + – +
Novus Biologicals NBP2-52524 – + + +
R&D Systems Mab397 – + – +
R&D Systems Mab3971 – – – +
Alomone Labs ANT-019 Rabbit – + – +
Biosensis R-1834 + + – +
Millipore Sigma HPA007637 + + – –
Abcam ab134155 + + –
R&D Systems AF1494 Goat – + – –February 2021 | Volume 12 | ArtiThis table summarizes the results obtained regarding the detection of the full-length (FL) and truncated (T1) isoforms of TrkB. +, detected; -, not detected.TABLE 4 | Summary of antibody performance for p75NTR.
p75NTR
Manufacturer Catalog no. Host Epitope Detection in cortex Detection in platelets
Santa Cruz Biotechnology sc-271708 Mouse ICD – ?
Millipore Sigma HPA004765 Rabbit ICD + +
Alomone Labs ANT-007 ECD + +
Alomone Labs ANT-011 ICD + +This table summarizes the results obtained regarding the detection of the full-length p75NTR receptor. +, detected; −, not detected; ?, uncertain. ECD, extracellular domain;
ICD, intracellular domain.cle 606861
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The identification of the TrkB and p75NTR receptors in platelets
opens new avenues of research, using platelets as peripheral
biomarkers of neurological expression patterns of these receptors.
Whereas circulating BDNF levels have been extensively studied
(34), little is known about the interplay between BDNF, proBDNF,
TrkB, and p75NTR in these easily available peripheral cells (51, 52).
The results presented herein highlighting structural differences
between TrkB and p75NTR receptors in human cortex and
platelets, raise the possibility that these receptors in platelets
might not be a true reflection of expression in the cerebral
cortex. A better characterization of the activity of TrkB and
p75NTR in platelets is warranted, to assess whether BDNF
receptors in platelets have an inherent biological role, and could
potentially be used to mirror receptor function in neuronal tissues.LIMITATIONS
While the many antibodies characterized represent a strength of
the present study, there are also noteworthy limitations. The fact
that all antibodies were tested on the exact same cortex sample
allowed a better comparison between antibodies themselves
because the differences observed for the cortex sample were not
due to unequal levels of receptors in the sample. However, we
recognize that the cerebral cortex might not be representative of
other brain regions, and the ratio between the multiple isoforms of
BDNF receptors are known to vary from a region to another (53).
Moreover, using a single donor does not allow representation of
inter-individual variation in levels of these receptors in cortical
tissues. The presence of TrkB and p75NTR has been shown solely
with antibody-based techniques. Since platelets are anucleate cells,
we could not verify antibody specificity in this cell type using
classic molecular biology approaches, such as knockout models,
and have had to rely on cross-verification with independent
antibodies, in the presence of cells/tissues with confirmed TrkB
and p75NTR expression. It is important to reconcile the results
presented herein with reports of absence of TrkB or p75NTR
receptors on human platelets (32, 42). The fact that only the
truncated isoform of TrkB lacking its tyrosine kinase domain has
been found in platelets in our study may explain why prior reports
using antibodies targeting the intracellular domain of TrkB
receptors would have failed, highlighting the importance of
confirming results with independent antibodies targeting
different epitopes of the receptor. Arguably, protein sequencing
by techniques such as mass spectrometry would further increase
confidence in the results.CONCLUSION
Our results suggest that human platelets express a truncated form of
the TrkB receptor and the full-length p75NTR receptor; structural or
post-translational differences from the isoforms expressed in the
central nervous system are apparent on receptormass. An important
aspect of this work is the tissue-specificity of some antibodies
targeting BDNF receptors, and a lack of reproducibility betweenFrontiers in Immunology | www.frontiersin.org 9antibodies, even within the same clonal selection. This highlights the
importance of careful characterization of antibodies when using
immuno-based assays to study BDNF receptors, both within and
beyond the central nervous system. A thorough characterization of
the TrkB and p75NTR isoforms in platelets and other circulating cells
is therefore critical before they can be recommended as models of
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Platelets Selectively Regulate the Release of BDNF, But Not That of Its
Precursor Protein, proBDNF. Front Immunol (2020) 11:575607:575607.
doi: 10.3389/fimmu.2020.575607
53. Ohira K, Shimizu K, Hayashi M. Change of expression of full-length and
truncated TrkBs in the developing monkey central nervous system. Brain Res
Dev Brain Res (1999) 112(1):21–9. doi: 10.1016/s0165-3806(98)00151-5
Conflict of Interest:ML has received speaker fees from Bayer; has participated in
industry-funded trials from Idorsia; has served on advisory boards for Servier; and
has received in-kind and financial support for investigator-initiated grants from
Leo Pharma, Roche Diagnostics, Aggredyne, and Fujimori Kogyo.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Fleury, Boukhatem, Le Blanc, Welman and Lordkipanidze.́ This is
an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.February 2021 | Volume 12 | Article 606861
